Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Cited by (1,004)

Items 501–600 of 1,004

1. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—Rather a Bystander Than a Driver of Mortality
   Georg Semmler, Sarah Wernly, Sebastian Bachmayer, Isabella Leitner, Bernhard Wernly, Matthias Egger, Lena Schwenoha, Leonora Datz, Lorenz Balcar, Marie Semmler et al. · 2021 · The Journal of Clinical Endocrinology & Metabolism
2. Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease
   Nobuharu Tamaki, Mayu Higuchi, Masayuki Kurosaki, Rohit Seth Loomba, Namiki Izumi, Kento Inada, Sakura Kirino, Koji Yamashita, Shuhei Sekiguchi, Yuka Hayakawa et al. · 2021 · Clinical Gastroenterology and Hepatology
3. Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
   Anne Linde Mak, Jenny Lee, Anne‐Marieke van Dijk, Yasaman Vali, Guruprasad Padur Aithal, Jörn Markus Schattenberg, Quentin Mark Anstee, M. Julia Brosnan, Mohammad Hadi Zafarmand, Dewkoemar Ramsoekh et al. · 2021 · Biomedicines
4. The role of microbiota in nonalcoholic fatty liver disease
   Agostino Di Ciaula, Leonilde Bonfrate, Piero Portincasa · 2022 · European Journal of Clinical Investigation
5. Screening strategy for non-alcoholic fatty liver disease
   Saisai Zhang, Lung‐Yi Mak, Man‐Fung Yuen, Wai‐Kay Seto · 2022 · Clinical and Molecular Hepatology
6. Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update
   Nicholas Chew, Cheng Han Ng, Emily Truong, Mazen Noureddin, Kris V. Kowdley · 2022 · Seminars in Liver Disease
7. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease
   Jingjing Jiao, Jessica I. Sanchez, Ómar A. Saldarriaga, Luisa Maren Solis, David John Tweardy, Dipen Maheshbhai Maru, Heather L. Stevenson, Laura Beretta · 2022 · JHEP Reports
8. Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients
   Weiwei Zhu, Hongqiang Li, Yu Yan, Jianan Chen, Xiao‐Long Chen, Fang Ren, Zhigang Ren, Guangying Cui · 2018 · Cancer Management and Research
9. Nonalcoholic fatty liver disease and portal hypertension
   Marvin K. Ryou, Nicholas Stylopoulos, György Baffy · 2020 · Exploration of Medicine
10. Case-finding strategies in non-alcoholic fatty liver disease
    Jérôme Boursier, Emmanuel A. Tsochatzis · 2020 · JHEP Reports
11. European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of fatty liver disease?
    Jeffrey Victor Lazarus, Adam Palayew, Patrizia Carrieri, Mattias Ekstedt, Giulio Marchesini, Katja Novak, Vlad Ratziu, Manuel Romero‐Gómez, Frank Tacke, Shira Zelber‐Sagi et al. · 2021 · JHEP Reports
12. NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea
    Jiyoon Park, Eunice Yewon Lee, Jie Li, Mi Jung Jun, Eileen Laureal Yoon, Sang Bong Ahn, Chuanli Liu, Hongli Yang, Fajuan Rui, Biyao Zou et al. · 2021 · Digestive Diseases
13. Preparing for the NASH epidemic: A call to action
    Fasiha Kanwal, Jay H. Shubrook, Zobair M. Younossi, Yamini Natarajan, Elisabetta Bugianesi, Mary Eugenia Rinella, Stephen A. Harrison, Christos Socrates Mantzoros, Kim M. Pfotenhauer, Samuel Klein et al. · 2021 · Metabolism
14. Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis
    Pennisi, Grazia, Enea, Marco, Romero‐Gomez, Manuel, Viganò, Mauro, Bugianesi, Elisabetta, Wong, Vincent W.‐S., Fracanzani, Anna Ludovica, Sebastiani, Giada, Boursier, Jerome, Berzigotti, Annalisa et al. · 2022 · Alimentary Pharmacology & Therapeutics
15. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population
    Joana Rigor, Andreia Cinara Branco Diegues, José Presa, Pedro Barata, Daniela Martins‐Mendes · 2022 · Postgraduate Medicine
16. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms
    Tinsay A. Woreta, Mark L. Van Natta, Mariana Lazo, Arunkumar Krishnan, Brent A. Neuschwander‐Tetri, Rohit Seth Loomba, Anna Mae Diehl, Manal F. Abdelmalek, Naga Chalasani, Samer Gawrieh et al. · 2022 · PLoS ONE
17. PNPLA3 Genotype and Risk of Liver and All‐Cause Mortality
    Stefan Stender, Rohit Seth Loomba · 2020 · Hepatology
18. Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
    Wirth, Eva K., Puengel, Tobias, Spranger, Joachim, Tacke, Frank · 2022 · Expert Review of Endocrinology & Metabolism
19. Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD
    Linge, Jennifer, Nasr, Patrik, Sanyal, Arun J., Dahlqvist Leinhard, Olof, Ekstedt, Mattias · 2023 · JHEP Reports
20. Astaxanthin Alleviates Nonalcoholic Fatty Liver Disease by Regulating the Intestinal Flora and Targeting the AMPK/Nrf2 Signal Axis
    Yuhang Li, Juxiong Liu, Bojian Ye, Yueyao Cui, Ruiqi Geng, Shu Liu, Yufei Zhang, Wenjin Guo, Shoupeng Fu · 2022 · Journal of Agricultural and Food Chemistry
21. Phenotypes of Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma
    Jesús Rivera‐Esteban, Sergio Muñoz, Mónica Higuera, Elena Sena, María Bermúdez-Ramos, Juan Bañares, María Martínez-Gómez, M Serra Cusidó, Alba Jiménez-Masip, Sven Francque et al. · 2024 · Clinical Gastroenterology and Hepatology
22. Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies
    Pegah Golabi, Soroor Owrangi, Zobair M. Younossi · 2024 · Alimentary Pharmacology & Therapeutics
23. Risk factors for biopsy‐proven advanced non‐alcoholic fatty liver disease in the Veterans Health Administration
    Yuval A. Patel, Elizabeth J. Gifford, Lisa M. Glass, Rebecca B. McNeil, Michael J. Turner, Byungjoo Han, Dawn Provenzale, Steven S. Choi, Cynthia A. Moylan, Christine M. Hunt · 2017 · Alimentary Pharmacology & Therapeutics
24. Tomoelastography for the Evaluation of Pediatric Nonalcoholic Fatty Liver Disease
    Christian A. Hudert, Heiko Tzschätzsch, Birgit D. Rudolph, Hendrik Bläker, Christoph Loddenkemper, Hans-Peter Müller, Stephan Henning, Philip Bufler, Bernd Hamm, Jürgen Braun et al. · 2018 · Investigative Radiology
25. Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy
    Wang, Yan, Wong, Grace Lai-Hung, He, Fang-Ping, Sun, Jian, Chan, Anthony Wing-Hung, Yang, Jinlian, Shu, Sally She-Ting, Liang, Xieer, Tse, Yee Kit, Fan, Xiao-Tang et al. · 2020 · Gut
26. Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non‐invasive score
    Zhuojun Xin, Yuanyue Zhu, Shuangyuan Wang, Shanshan Liu, Min Xu, Tiange Wang, Jieli Lu, Yuhong Chen, Zhiyun Zhao, Weiqing Wang et al. · 2019 · Liver International
27. The role of the sphingolipid pathway in liver fibrosis: an emerging new potential target for novel therapies
    Yuval Ishay, Dean Nachman, Tawfik Khoury, Yaron Ilan · 2020 · American Journal of Physiology-Cell Physiology
28. Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma
    D. Ramai, Waqqas Tai, Michelle Rivera, A. Facciorusso, N. Tartaglia, M. Pacilli, A. Ambrosi, C. Cotsoglou, R. Sacco · 2021 · Biomedicines
29. Screening for nonalcoholic fatty liver disease-when, who and how?
    Christoph G. Dietrich, Monika Rau, Andreas Geier · 2021 · World Journal of Gastroenterology
30. The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease
    Hao Xu, Lin Wang · 2021 · Frontiers in Molecular Biosciences
31. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)
    Christoph Roderburg, Sarah Krieg, Andreas H. Krieg, Münevver Demir, Tom Luedde, Karel Kostev, Sven Heiko Loosen · 2023 · European journal of medical research
32. Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study
    Tracey G. Simon, Fahim Ebrahimi, Björn Roelstraete, Hannes Hagström, Johan Sundström, Jonas Filip Ludvigsson · 2023 · Cardiovascular Diabetology
33. Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
    Eugene Han, Byung‐Wan Lee, Eun Seok Kang, Bong Soo, Sang Hoon Ahn, Yong‐ho Lee, Seung Up Kim · 2024 · Metabolism
34. Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis
    Zobair M. Younossi, Maria Stepanova, Andrei Racila, Linda L Henry, Dominic Labriola, Rebecca A. Taub, Fatema Nader · 2024 · Hepatology
35. Spirulina Liquid Extract Protects against Fibrosis Related to Non-Alcoholic Steatohepatitis and Increases Ursodeoxycholic Acid
    Marine Coué, Angela Tesse, Juliette Falewee, Audrey Aguesse, Mikaël Croyal, Lionel Fizanne, Julien Chaigneau, Jérôme Boursier, Khadija Ouguerram · 2019 · Nutrients
36. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy
    Salvatore Petta, Jie Ting, Stefania Saragoni, Luca Degli Esposti, Sanatan Shreay, Maria Letizia Petroni, Giulio Marchesini · 2020 · Nutrition Metabolism and Cardiovascular Diseases
37. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients
    Shunji Hirose, Koshi Matsumoto, Masayuki Tatemichi, Kota Tsuruya, Kazuya Anzai, Yoshitaka Arase, Koichi Shiraishi, Michiko Suzuki, Satsuki Ieda, Tatehiro Kagawa · 2020 · PLoS ONE
38. Long‐term prognosis of patients with alcohol‐related liver disease or non‐alcoholic fatty liver disease according to metabolic syndrome or alcohol use
    Marie Decraecker, Dan Dutartre, Jean‐Baptiste Hiriart, Marie Irlès‐Depé, Hortense Marraud des Grottes, Faïza Chermak, Juliette Foucher, Adèle Delamarre, Victor de Lédinghen · 2021 · Liver International
39. Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
    Alfred Sidney Barritt, Emma Marshman, Mazen Noureddin · 2022 · Alimentary Pharmacology & Therapeutics
40. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
    Daniel Clayton‐Chubb, William W. Kemp, Ammar Majeed, John Samuel Lubel, Alex Hodge, Stuart Keith Roberts · 2023 · Nutrients
41. Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease
    Paola Dongiovanni, Marica Meroni, Rosellina Margherita Mancina, Guido Baselli, Raffaela Rametta, Serena Pelusi, Ville Männistö, Anna Ludovica Fracanzani, Sara Badiali, Luca Miele et al. · 2018 · Hepatology Communications
42. Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
    Georg Semmler, Christian Datz, Michael Trauner · 2022 · Clinical and Molecular Hepatology
43. Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study
    Tracey G. Simon, Björn Roelstraete, Hannes Hagström, Rohit Seth Loomba, Jonas Filip Ludvigsson · 2023 · Journal of Hepatology
44. Surveillance of the liver in type 2 diabetes: important but unfeasible?
    Sami U. Qadri, Hannele Yki‐Järvinen · 2024 · Diabetologia
45. Bi-lobar liver biopsy via EUS enhances the assessment of disease severity in patients with non-alcoholic steatohepatitis
    Sandeep Khurana, Waseem Butt, Harshit S. Khara, Amitpal S. Johal, Sara West, Zongming E. Chen, Andrea L. Berger, David L. Diehl · 2019 · Hepatology International
46. Triglyceride glucose (TyG) index and the progression of liver fibrosis: A cross-sectional study
    Helda Tutunchi, Fatemeh Naeini, Majid Mobasseri, Alireza Ostadrahimi · 2021 · Clinical Nutrition ESPEN
47. Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
    Masato Yoneda, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Takaomi Kessoku, Kento Imajo, Asako Nogami, Masataka Taguri, Hiroyuki Kirikoshi, Satoru Saito et al. · 2022 · Hepatology Communications
48. Systematic review and meta‐analysis: Association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease
    Mohamad Jamalinia, Fatemeh Zare, Kamran Bagheri Lankarani · 2023 · Alimentary Pharmacology & Therapeutics
49. Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review
    Luca Rinaldi, Chiara Giorgione, Andrea Mormone, Francesca Esposito, Michele Rinaldi, Massimiliano Berretta, Raffaele Marfella, Ciro Pasquale Romano · 2023 · Viruses
50. Ginsenoside Rg5 inhibits lipid accumulation and hepatocyte apoptosis via the Notch1 signaling pathway in NASH mice
    Na Li, Chenhui Zhu, Rongzhan Fu, Xiaoxuan Ma, Zhiguang Duan, Daidi Fan · 2023 · Phytomedicine
51. Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
    Oksana M. Drapkina, Концевая Анна Васильевна, А. М. Калинина, Sergey Nikolaevich Avdeev, Агальцов Михаил Викторович, Л. И. Алексеева, I. I. Almazova, Е. Yu. Andreenko, D. N. Antipushina, Yu. А. Balanova et al. · 2024 · CARDIOVASCULAR THERAPY AND PREVENTION
52. Prevalence and severity of non‐alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital
    Thomas Marjot, Emilia Sbardella, Ahmad Moolla, Jonathan Hazlehurst, G. D. Tan, Mark Andrew Ainsworth, Jeremy Cobbold, Jeremy Tomlinson · 2017 · Diabetic Medicine
53. The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study
    Fuad Jafarov, Eda Kaya, Alev Bakır, Fatih Eren, Yusuf Nadir Yilmaz · 2019 · European Journal of Gastroenterology & Hepatology
54. Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease
    Benoit Smeuninx, Ebru Boslem, Mark Anthony Febbraio · 2020 · Cancers
55. Digital pathology: accurate technique for quantitative assessment of histological features in metabolic‐associated fatty liver disease
    David Martí Aguado, Alejandro Rodríguez, Claudia Mestre‐Alagarda, Mónica Elizabeth Bauza, Elena Valero‐Pérez, Clara Alfaro‐Cervelló, Salvador Benlloch, Judith Pérez‐Rojas, Antonio Ferrández, P Alemany Monraval et al. · 2020 · Alimentary Pharmacology & Therapeutics
56. Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis
    Agostino Di Ciaula, Leonilde Bonfrate, Marcin Jan Krawczyk, Gema Frühbeck, Piero Portincasa · 2022 · International Journal of Molecular Sciences
57. Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease
    Benedikt K. Kaufmann, Nick Seyfried, Daniel Hartmann, Phillipp Hartmann · 2023 · American Journal of Physiology-Gastrointestinal and Liver Physiology
58. Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD
    Salvatore Petta, Angelo Armandi, Elisabetta Bugianesi · 2024 · Liver International
59. Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
    Wenhao Li, William Alazawi, Rohit Seth Loomba · 2025 · The Lancet. Gastroenterology & hepatology
60. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis
    Vlad Ratziu, Marwan Ghabril, Manuel Romero‐Gómez, Gianluca Svegliati‐Baroni · 2018 · Transplantation
61. Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease
    Nobuharu Tamaki, Mayu Higuchi, Masayuki Kurosaki, Sakura Kirino, Leona Osawa, Keiya Watakabe, Wan Wang, Mao Okada, Takao Shimizu, Kenta Takaura et al. · 2019 · Scientific Reports
62. Long‐term outcomes of non‐alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population
    Tomomi Kogiso, Takaomi Sagawa, Kazuhisa Kodama, Makiko Taniai, Etsuko Hashimoto, Katsutoshi Tokushige · 2020 · Journal of Gastroenterology and Hepatology
63. Current and new pharmacotherapy options for non-alcoholic steatohepatitis
    Yoshio Sumida, Masato Yoneda, Yuji Ogawa, Masashi Yoneda, Takeshi Okanoue, Atsushi Nakajima · 2020 · Expert Opinion on Pharmacotherapy
64. Hepatic autophagy fluctuates during the development of non-alcoholic fatty liver disease
    Hao Ding, Ge Ge, Yujen Tseng, Yanyun Ma, Jun Zhang, Jie Liu · 2020 · Annals of Hepatology
65. Incretin combination therapy for the treatment of non-alcoholic steatohepatitis
    Kannt, Aimo, Madsen, Andreas Nygaard, Kammermeier, Claire, Elvert, Ralf, Klöckener, Tim, Bossart, Martin, Haack, Torsten, Evers, Andreas, Lorenz, Katrin, Hennerici, Wolfgang et al. · 2020 · Diabetes, Obesity and Metabolism
66. Enhanced liver Fibrosis® test predicts liver-related outcomes in the general population
    Kustaa Saarinen, Martti A. Färkkilä, Antti Jula, Iris Erlund, Terhi Vihervaara, Annamari Lundqvist, Fredrik O. Åberg · 2023 · JHEP Reports
67. Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects
    Søren Møller, Nina Kimer, Jens Dahlgaard Hove, Mads Barløse, Lise Lotte Gluud · 2025 · European Journal of Preventive Cardiology
68. Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non‐alcoholic fatty liver disease
    Kenichi Tanaka, Hirokazu Takahashi, Hideyuki Hyogo, Masafumi Ono, Noriko Oza, Yoichiro Kitajima, Miwa Kawanaka, Kazuaki Chayama, Toshiji Saibara, Keizo Anzai et al. · 2018 · Hepatology Research
69. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis
    Denise van der Graaff, Wilhelmus Josephus Kwanten, Sven Francque · 2018 · Medical Hypotheses
70. An Inhibitor of Arginine‐Glycine‐Aspartate‐Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis
    Barbara Ulmasov, Hidenao Noritake, Peter Carmichael, Kiyoko Oshima, David W. Griggs, Brent A. Neuschwander‐Tetri · 2018 · Hepatology Communications
71. Discordant pathological diagnosis of non‐alcoholic fatty liver disease: A prospective multicenter study
    Takuya Kuwashiro, Hirokazu Takahashi, Hideyuki Hyogo, Yuji Ogawa, Kento Imajo, Masato Yoneda, Takashi Nakahara, Satoshi Oeda, Kenichi Tanaka, Yuichiro Amano et al. · 2019 · JGH Open
72. The risk of atrial fibrillation in patients with non-alcoholic fatty liver disease and a high hepatic fibrosis index
    Hyo Eun Park, Heesun Lee, Su‐Yeon Choi, Hua Sun Kim, Goh Eun Chung · 2020 · Scientific Reports
73. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
    Gebran W. Khneizer, Syed Rizvi, Samer Gawrieh · 2020 · Advances in experimental medicine and biology
74. Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease
    Veeral H. Ajmera, Khang Nguyen, Nobuharu Tamaki, Suzanne R. Sharpton, Ricki Bettencourt, Rohit Seth Loomba · 2022 · Therapeutic Advances in Gastroenterology
75. Nonalcoholic Steatohepatitis — Opportunities and Challenges
    Guadalupe García–Tsao · 2021 · New England Journal of Medicine
76. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials
    Gu, Yunpeng, Sun, Lei, He, Yining, Yang, Luping, Deng, Chaohua, Zhou, Run, Kong, Tingting, Zhang, Wei, Chen, Yutong, Li, Jie et al. · 2023 · Expert Review of Gastroenterology & Hepatology
77. Efficacy and Safety of Fibroblast Growth Factor‐21 Analogs for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis: A Systematic Review and Meta‐Analysis
    Jeong, Changhyeon, Han, Nayoung, Jeon, Nakyung, Rhee, Su‐jin, Staatz, Christine E., Kim, Min‐Soo, Baek, In‐hwan · 2024 · Clinical Pharmacology & Therapeutics
78. Dietary Isoquercetin Reduces Hepatic Cholesterol and Triglyceride in NAFLD Mice by Modulating Bile Acid Metabolism via Intestinal FXR-FGF15 Signaling
    Ce Zhang, Zunji Shi, Hehua Lei, Fang Wu, Chuan Chen, Zheng Cao, Yuchen Song, Cui Zhang, Jinlin Zhou, Yu‐Jing Lu et al. · 2023 · Journal of Agricultural and Food Chemistry
79. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies
    Koen C. van Son, L.C. te Nijenhuis-Noort, Sebastiaan C. Boone, Dennis Owen Mook-Kanamori, Adriaan Georgius Holleboom, Paul R. Roos, Hildo J. Lamb, Gabrielle Alblas, Minneke J. Coenraad, Frits Richard Rosendaal et al. · 2024 · Medicine
80. Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
    Young Eun Chon, Young‐Joo Jin, Jihyun An, Hee Yeon Kim, Miyoung Choi, Dae Won Jun, Mi Na Kim, Ji Won Han, Han Ah Lee, Jung Hwan Yu et al. · 2024 · Clinical and Molecular Hepatology
81. Serotonergic regulation of energy metabolism in peripheral tissues
    Wonsuk Choi, Joon Ho Moon, Hail Kim · 2020 · Journal of Endocrinology
82. An update on drug development for the treatment of nonalcoholic fatty liver disease – from ongoing clinical trials to future therapy
    Monika Rau, Andreas Geier · 2021 · Expert Review of Clinical Pharmacology
83. Effect of hepatic steatosis on native T1 mapping of 3T magnetic resonance imaging in the assessment of T1 values for patients with non-alcoholic fatty liver disease
    Jhii-Hyun Ahn, Jeong‐Sik Yu, Kyu‐Sang Park, Seong Hee Kang, Ji Hye Huh, Jae Seung Chang, Jong-Han Lee, Moon Young Kim, Dominik Marcel Nickel, Stephan Kannengießer et al. · 2021 · Magnetic Resonance Imaging
84. Natural history of NASH
    Angelo Armandi, Elisabetta Bugianesi · 2021 · Liver International
85. Modulation of gut microbiota by glycyrrhizic acid may contribute to its anti-NAFLD effect in rats fed a high-fat diet
    Sai Wang, Xinyu Li, Hong‐Fang Ji, Liang Shen · 2022 · Life Sciences
86. Machine learning approaches for early detection of non-alcoholic steatohepatitis based on clinical and blood parameters
    Amir Reza Naderi Yaghouti, Hamed Zamanian, Ahmad Shalbaf · 2024 · Scientific Reports
87. Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis
    Marc Gurun, Paul Brennan, Sava Handjiev, Aseil Khatib, Damien Leith, John Francis Dillon, Christopher J. Byrne · 2024 · PLoS ONE
88. Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice
    Anne S. Henkel, Sadiya S. Khan, Shantel Olivares, Toshio Miyata, Douglas E. Vaughan · 2018 · Hepatology Communications
89. The evolving role of liver biopsy in non-alcoholic fatty liver disease
    Juan Pablo Arab, Francisco Barrera M., Marco A. Arrese · 2018 · Annals of Hepatology
90. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients
    Amanda C. Cheung, Carlos Jose Figueredo, Mary Eugenia Rinella · 2019 · The American Journal of Gastroenterology
91. Clinical significance of elevated liver transaminases in HIV-infected patients
    Jia Xi Cai, Maria Osikowicz, Giada Sebastiani · 2019 · AIDS
92. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease
    Toshihide Shima, Kyoko Sakai, Hirohisa Oya, Takayuki Katayama, Yasuhide Mitsumoto, Masayuki Mizuno, Yoshihiro Kanbara, Takeshi Okanoue · 2019 · Journal of Gastroenterology
93. Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low‐Density Lipoprotein Cholesterol
    Christian Labenz, Jürgen H. Prochaska, Yvonne Huber, Michael Nagel, Beate Katharina Straub, Philipp Sebastian Wild, Peter R. Galle, Jörn Markus Schattenberg · 2019 · Hepatology Communications
94. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
    Yoshio Sumida, Masashi Yoneda, Yuya Seko, Hiroshi Ishiba, Tasuku Hara, Hidenori Toyoda, Satoshi Yasuda, Takashi Kumada, Hideki Hayashi, Takashi Kobayashi et al. · 2020 · Diagnostics
95. Triantennary GalNAc Molecular Imaging Probes for Monitoring Hepatocyte Function in a Rat Model of Nonalcoholic Steatohepatitis
    Anurag Kumar Mishra, Tamara R. Castañeda, Erik Bader, Bettina Elshorst, Sheila Cummings, Petra Scherer, Dinesh S. Bangari, Claudia Loewe, Herman Schreuder, Christoph Pöverlein et al. · 2020 · Advanced Science
96. Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait
    Faisal M. Sanai, Abdullah Al Khathlan, Ahmad Fadhli, Ahmad S. Jazzar, Almoutaz H. Hashim, Eid Mansour, Faisal Abdulrahman Abaalkhail, Fuad A. Hasan, Hajer Y. Al Mudaiheem, Huda Al Quraishi et al. · 2021 · Hepatology International
97. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study
    Yuko Nagaoki, Hideyuki Hyogo, Yuwa Ando, Yumi Kosaka, Shinsuke Uchikawa, Yuno Nishida, Yuji Teraoka, Kei Morio, Hatsue Fujino, Atsushi Ono et al. · 2021 · BMC Gastroenterology
98. Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease
    Suzanne R. Sharpton, Nobuharu Tamaki, Ricki Bettencourt, Egbert V. Madamba, Jinho Jung, Amy Y Liu, Cynthia A. Behling, Mark A. Valasek, Rohit Seth Loomba · 2021 · Therapeutic Advances in Gastroenterology
99. Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease
    Ajay Kumar. Duseja, Shivaram Prasad Singh, Manu Mehta, S. Shalimar, Jayanthi Venkataraman, Varun Mehta, Krishnadas Devadas, Sanjib K. Kar, Omesh Goyal, Aabha S. Nagral et al. · 2022 · Metabolic Syndrome and Related Disorders
100. Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD
     Nobuharu Tamaki, Kento Imajo, Suzanne R. Sharpton, Jinho Jung, Nancy Sutter, Nobuyoshi Kawamura, Masato Yoneda, Mark A. Valasek, Cynthia A. Behling, Claude B. Sirlin et al. · 2022 · Clinical Gastroenterology and Hepatology